Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years (NVX_PCV20)
COVID-19, Pneumococcal Infections
About this trial
This is an interventional prevention trial for COVID-19
Eligibility Criteria
Inclusion Criteria: Age: 60 years or older Males and females Able and willing (in the investigator's opinion) to comply with all study requirements. Participants, who already received three Covid-19 vaccines, of which the third was a mRNA vaccine (BNT162b2 or mRNA-1273) and at least 16 weeks ago Only applicable for women: last menstrual bleeding more than one year ago Exclusion Criteria: Use of immunosuppressants Congenital or acquired immunodeficiency (eg, history of HIV infection, hematological disease, current malignancy, or others) Chronic condition that may significantly interfere with the immune response in the opinion of the investigator History of Covid-19 within 16 weeks before study vaccination Previous pneumococcal vaccination Contraindication against any ingredient of the NVX or the PCV20 vaccine
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Experimental
Placebo Comparator
NVX arm
PCV20 arm
Combination arm
Placebo arm
NVX plus placebo
PCV20 (Apexxnar®) plus placebo
NVX plus PCV20
Placebo (normal saline) plus placebo